PMID- 33261658
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Dec 1
TI  - What is the impact of human umbilical cord mesenchymal stem cell transplantation 
      on clinical treatment?
PG  - 519
LID - 10.1186/s13287-020-02011-z [doi]
LID - 519
AB  - BACKGROUND: Human umbilical cord mesenchymal stem cells (HUC-MSCs) present in the 
      umbilical cord tissue are self-renewing and multipotent. They can renew 
      themselves continuously and, under certain conditions, differentiate into one or 
      more cell types constituting human tissues and organs. HUC-MSCs differentiate, 
      among others, into osteoblasts, chondrocytes, and adipocytes and have the ability 
      to secrete cytokines. The possibility of noninvasive harvesting and low 
      immunogenicity of HUC-MSCs give them a unique advantage in clinical applications. 
      In recent years, HUC-MSCs have been widely used in clinical practice, and some 
      progress has been made in their use for therapeutic purposes. MAIN BODY: This 
      article describes two aspects of the clinical therapeutic effects of HUC-MSCs. On 
      the one hand, it explains the benefits and mechanisms of HUC-MSC treatment in 
      various diseases. On the other hand, it summarizes the results of basic research 
      on HUC-MSCs related to clinical applications. The first part of this review 
      highlights several functions of HUC-MSCs that are critical for their therapeutic 
      properties: differentiation into terminal cells, immune regulation, paracrine 
      effects, anti-inflammatory effects, anti-fibrotic effects, and regulating 
      non-coding RNA. These characteristics of HUC-MSCs are discussed in the context of 
      diabetes and its complications, liver disease, systemic lupus erythematosus, 
      arthritis, brain injury and cerebrovascular diseases, heart diseases, spinal cord 
      injury, respiratory diseases, viral infections, and other diseases. The second 
      part emphasizes the need to establish an HUC-MSC cell bank, discusses 
      tumorigenicity of HUC-MSCs and the characteristics of different in vitro 
      generations of these cells in the treatment of diseases, and provides technical 
      and theoretical support for the clinical applications of HUC-MSCs. CONCLUSION: 
      HUC-MSCs can treat a variety of diseases clinically and have achieved good 
      therapeutic effects, and the development of HUC-MSC assistive technology has laid 
      the foundation for its clinical application.
FAU - Xie, Qixin
AU  - Xie Q
AD  - Anhui Key Laboratory, Department of Pharmacy, Yijishan Hospital Affiliated to 
      Wannan Medical College, Wuhu, China.
FAU - Liu, Rui
AU  - Liu R
AD  - Department of Medical Laboratory, Yijishan Hospital of Wannan Medical College, 
      Wuhu, China.
FAU - Jiang, Jia
AU  - Jiang J
AD  - Anhui Key Laboratory, Department of Pharmacy, Yijishan Hospital Affiliated to 
      Wannan Medical College, Wuhu, China.
FAU - Peng, Jing
AU  - Peng J
AD  - Anhui Key Laboratory, Department of Pharmacy, Yijishan Hospital Affiliated to 
      Wannan Medical College, Wuhu, China.
FAU - Yang, Chunyan
AU  - Yang C
AD  - Anhui Key Laboratory, Department of Pharmacy, Yijishan Hospital Affiliated to 
      Wannan Medical College, Wuhu, China.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Anhui Key Laboratory, Department of Pharmacy, Yijishan Hospital Affiliated to 
      Wannan Medical College, Wuhu, China.
FAU - Wang, Sheng
AU  - Wang S
AD  - Anhui Key Laboratory, Department of Pharmacy, Yijishan Hospital Affiliated to 
      Wannan Medical College, Wuhu, China.
FAU - Song, Jing
AU  - Song J
AD  - Anhui Key Laboratory, Department of Pharmacy, Yijishan Hospital Affiliated to 
      Wannan Medical College, Wuhu, China. livelypretty@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201201
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Cell Differentiation
MH  - Chondrocytes
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation
MH  - *Mesenchymal Stem Cells
MH  - Umbilical Cord
PMC - PMC7705855
OTO - NOTNLM
OT  - Clinical application
OT  - Human umbilical cord mesenchymal stem cells
OT  - Therapy
COIS- The authors declare that they have no competing interests.
EDAT- 2020/12/03 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/12/01
CRDT- 2020/12/02 05:21
PHST- 2020/07/14 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/12/02 05:21 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - 10.1186/s13287-020-02011-z [pii]
AID - 2011 [pii]
AID - 10.1186/s13287-020-02011-z [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Dec 1;11(1):519. doi: 10.1186/s13287-020-02011-z.